2026 Deloitte Life Sciences Executive Outlook: Growth Optimism Meets Resilience Challenges
Deloitte’s 2026 Life Sciences Executive Outlook finds that most biopharma and medtech leaders are optimistic about their own financial prospects for the coming year, but global economic and regulatory uncertainty tempers broader industry confidence. The report highlights that resilience, digital transformation (particularly AI adoption), and strategic investment in innovation will be key priorities for sustaining growth and navigating pricing, policy, and geopolitical pressures in 2026. 
2026 Deloitte Life Sciences Executive Outlook: Growth Optimism Meets Resilience Challenges